Approved Study Database

Ref. No. Scientific Title Principal investigator
2020.032 Health and Economic Impacts of Pre-Diabetes, Gestational Diabetes, Type 1 and Type 2 Diabetes in Hong Kong Dr. LUK Andrea On Yan
陸安欣
2020.438 Delineating the metabolic architecture and response to anti-hyperglycaemic drug treatment in lean type 2 diabetes in Chinese Dr. LUK Andrea On Yan
2021.164 Randomised, double-blind (within dose groups), placebo-controlled and parallel group trial to investigate the effects of different doses of oral BI 685509 given over 20 weeks on UACR reduction in patients with diabetic kidney disease. Dr. LUK Andrea On Yan
2022.404 Healthcare utilisation and diseases in people with and those without diabetes in Hong Kong before and after COVID-19 pandemic Prof Luk Andrea On Yan
2022.148 A Multicenter, Double-blind, Randomized, Placebo-Controlled, Phase II/III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of JT001 (VV116) for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Participants with Mild to Moderate COVID-19 Dr. LUK Andrea On Yan
陸安欣
2023.314 A PHASE I STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7565020 IN HEALTHY PARTICIPANTS AND IN PARTICIPANTS WITH CHRONIC HEPATITIS B VIRUS INFECTION Prof. LUK Andrea On Yan
2023.369 Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk Prof. LUK Andrea On Yan
2021.501 An Open-Label, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (BIIB098) in Chinese and Caucasian Adult Healthy Participants Dr. LUK Andrea On Yan
陸安欣
2012.482 Descriptive study of clinical profile of Hong Kong diabetic population Dr Luk Andrea On Yan
2025.145 Unravelling the pathogenicity of genetic variants in Wolfram Syndrome 1 gene in Chinese with young-onset diabetes Prof. LUK Andrea On Yan
Andrea On Yan Luk
2024.466 A Randomised, Double-blind, Placebo-controlled, Multi-centre, Sequential Phase II, and Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 Administered for up to 52 Weeks in Participants with Dyslipidaemia Prof. LUK Andrea On Yan
2024.159 Implementation of a novel diabetes prevention programme in Hong Kong Chinese workforce at high risk of type 2 diabetes Prof. LUK Andrea On Yan
2022.634 A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus Prof. LUK Andrea On Yan
陸安欣
2014.385 Best practice of holistic care: A case study approach Dr. LUK Andrew Leung
2025.103 CQI Project: Enhancing Triage Assessment to Identify Patients Eligible for Nurse-Initiated Water Cooling for Burn Injuries Mr. Luk Cheuk ho
2007.365 Longitudinal Change in Mental Competence for Treatment Decision in Chinese Older Adults with Congitive Impairment Dr. LUK Daisy Nga Yan
2023.237 Clinical Characteristics and Outcomes of Infections due to carbapenem-resistant Enterobacterales in Hong Kong Dr. LUK Fion Wing Lam
2016.035 Whole–body vibration training for residents in a care and attention home in Hong Kong and its influence on balance and mobility: a pilot study Ms. LUK Ho Yan
陸可欣
2008.401 The Effect of Vital Signs Obtained at Prehospital and Emergency Department's Triage Station on Impatient Admission Miss LUK Joies Ka Yan
2009.414 The effect of visual stimulation on the adult patient Mr. LUK Kar Yiu
2013.399 Focused Ultrasound Screening for Precutaneous Dilatational Tracheostomy Dr. LUK Leona Wing Kun
2008.190 Efficacy and Safety of Topical Photodynamic Therapy for Actinic Keratosis among Chinese Patients Dr. LUK Nai Ming
2011.493 Hand eczema among inhabilitants of a public housing estate in Hong Kong: a self-administered questionnaire survey Dr Luk Nai Ming
2007.318 Efficacy and Safety of Diphencyprone (DCP) in the Treatment of Extensive Alopecia Areata in Chinese Patient Dr. LUK Nai Ming
2009.437 Efficacy of intralesional 5-fluorouracil in treatment of keloid scar : a randomized-control trial Dr. LUK Nai Ming
2013.347 Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei Dr. LUK Sally Wai Yin
2014.406 Effects of thromboelastography-guided transfusion algorithm versus standard clinical practice on post-operative bleeding and blood product use after cardiac surgery: a randomized, controlled trial Dr. LUK Ting Hin
2005.471 Infliximab Induction Therapy for Moderate-to Severe Plaque-Type Psoriasis: An Open-Label, Single Arm Observational Study Evaluating the Efficacy of Use In Hong Kong Chinese Patients Prof. LUK Tommy Nai Ming
2023.551 Impact of Injury Prevention Program on Ankle stability for ballet dancers Ms. LUK Tsz Yan
2005.264 Psychological Distress, Quality of Life and Marital Relationship among Renal Patients Receiving Continuous Ambulatory Peritoneal Dialysis Ms. LUK Yvonne Pik Shan
2012.439 Cross Sectional Survey on Advance Care Planning Acceptance & End of Life Care Preferences among community dwelling elderly with complex medical problems and their carers Dr LUM Chor Ming
2015.247 Metformin-associated lactic acidosis requiring intensive care in regional hospitals in Hong Kong and predictive factors for mortality Dr. LUN Chung Tat
2020.411 A one–year prospective study for intrapleural pressure for thoracentesis Dr. LUN Chung Tat
2021.245 A COPD control questionnaire in a regional hospital during covid-19 pandemic Dr. Lun Chung Tat
2021.246 an asthma control questionnaire in a regional hospital during covid-19 pandemic Dr. LUN Chung Tat
2018.407 Prospective observational cohort study to assess the ability of mechanically-ventilated patients to press buttons on a smartphone application Miss LUNG Catherine Chi Yan
2008.417 An Asia Pacific Non-Randomized, Open-Label Phase II Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab (Erbitux) or FOLFOX Plus Cetuximab as First-Line Therapy in Subjects with KRAS Wild-Type Metastatic Colorectal Cancer (APEC-Study) Prof. MA Brigette
2024.264 A nurse-led lifestyle modification intervention for enhancing self-efficacy, illness perception, self-care management and steatosis grade among patients with metabolic dysfunction-associated steatotic liver disease: A pilot randomised controlled trial Ms. MA Angel Cho Kan
2023.300 A nurse-led lifestyle modification intervention for enhancing self-efficacy, illness perception, self-care management and steatosis grade among patients with non-alcoholic fatty liver disease: A randomised controlled trial Ms. MA Angel Cho Kan
2023.693 Perspectives on illness perception and self-management behaviours from patients with non-alcoholic fatty liver disease and healthcare professionals: An exploratory qualitative study Ms. MA Angel Cho Kan
2022.262 A phase I, open-label, multi-center study of KFA115 as a single agent and in combination with pembrolizumab in patients with select advanced cancers Prof. MA Brigette
2022.243 daNIS-3: An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic colorectal cancer (mCRC) Prof. MA Brigette
馬碧如教授
2012.118 Intensification of pre-operative therapy with multi-agent chemotherapy and concurrent chemoradiotherapy prior to total mesorectal excision surgery in patients with high risk rectal cancer Prof. MA Brigette
2010.604 Multicenter Phase II Study of MK-2206 in Previously Treated Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma Prof. MA Brigette
2009.486 A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer Associate Professor Ma Brigette
2012.192 A pilot case-control study of second or third line treatment with cetuximab-containing chemotherapy in patients with metastatic colorectal cancer who were previously treated with cetuximab-based chemotherapy Prof. MA Brigette
2008.141 A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer Prof. MA Brigette
2009.222 A phase I dose escalation, multi-center, open-label study of HSP990 administered orally in adult patients with advanced solid malignancies Prof. Ma Brigette
2009.223 A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma Professor Ma Brigette
2008.091 Multi-Centre International Study of Capecitabine + Bevacizumab as Adjuvant Treatment of Colorectal Cancer (QUASAR 2) Associate Professor Ma Brigette

Page 163 of 262.